Fill out the form below to watch the webinar
In this webinar, industry leaders share their assessment of the current status and main challenges facing the T cell therapy manufacturing community. Additionally, lessons learned on transitioning from autologous to allogeneic workflows is discussed, and how this may impact the future of cell therapy manufacturing.
Topics covered:
- Challenges of autologous neo-antigen TCR T cell therapy manufacturing
- Closed modular cell therapy workflow solutions
- Harnessing next-generation genome editing to develop allogeneic cell therapies
- Improving therapeutic success through process development and allogeneic manufacturing